Longeveron Inc.

Longeveron Inc. Annual Report - A Financial Overview for Investors

Longeveron Inc.'s recent 10-K filing offers a critical look at its financial health and strategic direction. This summary distills key information for retail investors, highlighting the company's performance and position in the competitive biotechnology landscape.

Company Overview & Strategic Focus

Longeveron Inc. is a clinical-stage biotechnology company that develops novel cellular therapies for age-related and life-threatening conditions. Its lead product candidate, Lomecel-B, is a cell therapy derived from donor bone marrow. Longeveron is advancing Lomecel-B through clinical trials for several key conditions:

• Hypoplastic Left Heart Syndrome (HLHS): A rare and life-threatening congenital heart defect in infants, currently in a Phase 2b clinical trial.
• Alzheimer's Disease (AD) Frailty: A condition characterized by physical decline in Alzheimer's patients, currently in a Phase 2a clinical trial.
• Aging Frailty: An earlier-stage indication.

As a "smaller reporting company" and "emerging growth company," Longeveron operates with reduced reporting requirements. While this lowers administrative costs, it also means less detailed public disclosure than larger, more established firms provide. On June 30, 2025, the company's market capitalization stood at approximately $16.5 million, a figure consistent with its early-stage development. As of March 9, 2026, outstanding shares totaled approximately 21.8 million Class A common stock and 1.5 million Class B common stock.

Financial Performance (Fiscal Year Ended December 31, 2025)

In the fiscal year ending December 31, 2025, Longeveron generated total revenue of approximately $1.5 million. Revenue primarily came from:

• Clinical Trial Revenue: Approximately $0.5 million from its involvement in clinical studies.
• Contract Manufacturing Revenue / Lease Revenue: Approximately $0.7 million from manufacturing services or facility leasing to third parties.
• NIH Grants: Approximately $0.3 million in non-dilutive funding from the National Institutes of Health for its research.

Despite these revenue streams, the company posted a significant net loss of approximately $25 million for the fiscal year. This loss primarily stemmed from the substantial research and development (R&D) expenses typical of clinical-stage biotech operations. A notable business activity was a supply agreement with Secretome Therapeutics Incorporated, initiated in February 2024, which boosted its contract manufacturing revenue.

Management's Discussion and Analysis (MD&A) Highlights

Management's discussion reveals Longeveron's operational focus and financial challenges. The $25 million net loss in fiscal year 2025 primarily reflects substantial investment in research and development (R&D) activities, essential for advancing Lomecel-B through its clinical trial phases. R&D expenses cover clinical trial conduct, investigational product manufacturing, and personnel. General and administrative expenses also contribute to the company's spending, supporting corporate infrastructure and public company compliance.

Recognizing the capital-intensive nature of biotech development, the company actively pursued capital raises to fund operations and clinical development. Successful private placements in Q4 2025 and March 2026 were crucial for maintaining liquidity. However, management explicitly raised concerns about the company's "ability to continue as a going concern." This means current capital, even with recent raises, may not sustain operations for the next 12 months without additional financing. This assessment underscores the critical need for ongoing capital acquisition and careful cash management. The supply agreement with Secretome Therapeutics Incorporated aims to generate additional revenue and leverage existing capabilities.

Competitive Position

The biotechnology industry, especially cellular therapies, is highly competitive and rapidly evolving. Longeveron competes with many pharmaceutical, biotechnology, and academic institutions developing or having developed treatments for age-related and life-threatening conditions like HLHS, Alzheimer's disease, and frailty. Key competitive factors include:

• The safety and efficacy of product candidates.
• The stage of development and speed to market.
• Proprietary position and intellectual property protection.
• Manufacturing capabilities and cost-effectiveness.
• Access to capital and strategic partnerships.

While Longeveron believes Lomecel-B, with its unique mechanism of action, shows promise, many competitors possess greater financial, technical, and human resources. They also often have more experience in clinical development, regulatory affairs, manufacturing, and commercialization. Effective competition hinges on Longeveron's success in clinical trials, obtaining regulatory approvals, protecting its intellectual property, and securing necessary funding.

Financial Health (Debt, Cash, Liquidity)

Longeveron's financial health relies heavily on equity financing to fund operations. On December 31, 2025, the company reported cash and cash equivalents of approximately $5 million. Subsequent capital raises significantly bolstered this cash position, including approximately $7 million from a Q4 2025 private placement and an additional $15 million from a March 11, 2026 private placement. These infusions are critical for maintaining liquidity and funding ongoing R&D.

The company's explicit "going concern" statement highlights its dependence on securing substantial additional financing to meet future operational needs. This signals a high level of liquidity risk.

Key Risks for Investors

Longeveron highlights several significant risks for investors:

1. Need for Additional Capital & Dilution: The most pressing risk is the continuous need for substantial additional capital to fund ongoing clinical trials and operations. Failure to secure this funding could severely impact the company's viability, and future capital raises will likely further dilute existing shareholders.
2. Clinical Trial Success is Not Guaranteed: The success of Lomecel-B is paramount. Clinical trials are inherently uncertain; there is no guarantee Lomecel-B will prove safe and effective in later-stage trials or achieve its primary endpoints (key goals). Negative trial results would significantly harm the company's prospects.
3. Regulatory Hurdles: Obtaining regulatory approval from agencies like the U.S. Food and Drug Administration (FDA) is a lengthy, complex, and expensive process with no guarantee of success.
4. Intense Competition: The biotech sector is highly competitive. Other companies may develop similar or superior treatments or bring products to market faster.
5. Manufacturing and Commercialization Challenges: Even if approved, Longeveron faces challenges scaling up manufacturing, establishing distribution, and successfully commercializing its product candidates.
6. Intellectual Property Protection: The company's value relies heavily on protecting its intellectual property rights (patents, trade secrets). Failure to do so could allow competitors to replicate its innovations.
7. Talent Acquisition and Retention: Attracting and retaining highly skilled scientific and management personnel is crucial for a development-stage biotech company.

Future Outlook & Strategic Priorities

Longeveron's immediate future focuses on advancing its lead product candidate, Lomecel-B, through ongoing clinical trials for HLHS and AD Frailty. Key strategic priorities include:

• Successfully completing the Phase 2b trial for HLHS and the Phase 2a trial for AD Frailty.
• Analyzing trial data to inform potential progression to later-stage clinical development or regulatory submissions.
• Actively seeking additional non-dilutive funding (like grants) and strategic partnerships to support its pipeline.
• Efficiently managing cash resources while continuing to explore new indications for Lomecel-B.

While recent capital raises offer a temporary lifeline, the company's long-term viability hinges on achieving positive clinical trial outcomes and securing further substantial funding.